Ocugen, Inc. (OCGN)
2025-06-30 | 2024-06-30 | |||
|---|---|---|---|---|
| Total revenue | - | 1,141 | ||
| Research and development | - | 8,902 | ||
| General and administrative | - | 7,688 | ||
| Total operating expenses | - | 16,590 | ||
| Loss from operations | - | -15,449 | ||
| Other income (expense), net | - | 169 | ||
| Net loss | - | -15,280 | ||
| Redeemed series b convertible preferred stock | - | -4,988 | ||
| Net loss available to common shareholders— basic | - | -10,292 | ||
| Net loss available to common shareholders— diluted | - | -10,292 | ||
| Net loss attributable to shareholders - basic | - | - | ||
| Net loss attributable to shareholders - diluted | - | -10,292 | ||
| Basic eps | - | -0.04 | ||
| Diluted eps | - | -0.04 | ||
| Basic average shares | - | 257,353,857 | ||
| Diluted average shares | - | 257,353,857 | ||
| Net loss per share attributable to shareholders - basic (in usd per share) | - | - | ||
| Net loss per share attributable to shareholders - diluted (in usd per share) | - | - | ||
| Weighted shares used in calculating net loss per share - basic (in shares) | - | - | ||
| Weighted shares used in calculating net loss per share - diluted (in shares) | - | - | ||